Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, double-blind, placebo-controlled, parallel-group study to explore the safety and tolerability of doses of E2007 [perampanel] up to a maximum of 12 mg in patients with refractory partial seizures

Next Previous
Trial Profile

A randomized, double-blind, placebo-controlled, parallel-group study to explore the safety and tolerability of doses of E2007 [perampanel] up to a maximum of 12 mg in patients with refractory partial seizures

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 05 Oct 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Perampanel (Primary)
  • Indications Partial epilepsies
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 05 Dec 2017 Results of post hoc analysis of open label extension studies, presented at the 71st Annual Meeting of the American Epilepsy Society.
  • 21 Jun 2012 Additional trial locations identified as reported by EudraCT.
  • 01 Jan 2012 Results published in Acta Neurologica Scandinavica.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top